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Abstract
Summary Telephone call intervention did not improve alendronate persistence in Fracture Liaison Service (FLS) patients in this
study. A bone turnover marker cut-off point for alendronate persistence is proposed for individual FLS patients.
Introduction FLS aims to prevent subsequent fractures, which should include improving patients’ persistence with prescribed
oral bisphosphonates. We studied the influence of telephone calls and the predictive value of changes in bone turnover markers
(BTMs) for evaluating persistence with alendronate.
Methods Postmenopausal women with a recent fracture and osteoporosis who started alendronate were randomized to receive
three phone calls (PC) (after 1, 4, and 12 months) or no phone calls (no PC). s-CTX and P1NP were measured at baseline and
after 3, 6, 9, and 12months. As a reference group, 30 postmenopausal osteopenic patients with a recent fracture were analyzed as
well. Persistencewas assessed using the Dutch National Switch Point Pharmacies-GPs database and cross-referencedwith PC, no
PC, and BTM changes. Cut-off values of BTMs were calculated based on least significant change (LSC) and also on underrun-
ning median values of the untreated osteopenic postmenopausal reference group with a recent fracture.
Results Out of 119 patients, 93 (78%) completed 12 months follow-up (45 PC and 48 no PC). Mean age was 69 years. Persistence
was similar in PC and no PC participants. The cut-off value > 29% (< 415 ng/L) as LSC of s-CTX and > 36% (< 53.1 μg/L) as LSC
of P1NP was determined optimally showing alendronate persistence after 1 year (being 93 and 88%, respectively).
Conclusions In this context, telephone calls did not improve persistence. In around 90% of patients, 1-year alendronate persis-
tence was confirmed by achieving LSC of s-CTX and of P1NP at 12 months.
Keywords alendronate . capture theFracture®BestPracticeFramework .Medicationdispensation .P1NP .pharmacydeliveries .
s-CTX
Introduction
The Fracture Liaison Service (FLS) is advocated as the most
appropriate approach for secondary fracture prevention in
patients with osteoporosis [1, 2]. Besides successful preven-
tion of subsequent fractures, FLS activities have been shown
to reduce mortality [3]. The FLS concept and its necessity
were first reported by the Glasgow group [4, 5]. The concept
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includes full diagnostic evaluation with a focus on detecting
underlying disorders and determining the appropriate tailor-
made treatment. The International Osteoporosis Foundation
(IOF) introduced the Capture The Fracture® (CtF) Best
Practice Framework (BPF), which consists of 13 standards
for evaluating the performance of any FLS, however not in-
cluding telephone intervention nor taking lab samples for
bone turnover markers (BTMs) [6]. The current study pertains
to BPF standard 12, i.e., to ascertain what processes are in
place to ensure that long-term management of fracture risk is
reliably provided [6].
Recently, inventories on CtF criteria analyzed FLS quali-
ties worldwide [7–9], and our own group reported nationwide
on 24,418 Dutch patients [10]. The principal weakness was an
FLS attendance of 49% [10]. Notably, all recent fracture pa-
tients older than 50 received invitations for follow-up in line
with the Dutch Guideline on Osteoporosis and Falls [11].
Besides low numbers of patients attending, a second concern
is the low persistence with treatments. In the Netherlands, a
nationwide survey of medication dispensation showed up to
40% persistence for anti-osteoporosis medication during
12 months [12]. These findings were obtained from the med-
ication dispensation database on osteoporosis medication,
which was generated by IMS Health based on Dutch nation-
wide data of most pharmacies’ sales to patients. Contrarily, a
recent study indicated a much higher persistence of 75% in
patients with a recent fracture [13]. Therefore, we hypothe-
sized that persistence in recently fractured patients may be
improved by means of telephone calls during the first year
of follow-up. Telephone initiatives to improve persistence
with bisphosphonates have been tested previously, yet not in
patients attending FLS [14–26] (Table 1).
In this study, the primary objective was to compare the
effect of a dedicated telephone call intervention with standard
FLS care on persistence with bisphosphonates at 12 months.
The secondary objective was to analyze if BTMs are markers
of persistence verified by pharmacy deliveries in LSP.
Patients and methods
Study procedure
Consecutive female patients who attended the FLS due to a
recent non-vertebral or clinical vertebral fracture were included
if they were 50 years or older. In each patient, treatment was
initiated in line with the Dutch Guideline on Osteoporosis and
Falls [11]. This guideline recommends treatment in case of a T-
score of − 2.5*SD or less, or a T-score between − 1.0 and
2.5*SD and prevalent vertebral fractures on Vertebral Fracture
Assessment (VFA). Patients were excluded in case of metabolic
bone disorders. Vitamin D deficiency without secondary hyper-
parathyroidism was not an exclusion criterion.
All patients with osteoporosis and osteopenia received
FLS standard care, including lifestyle and nutrition edu-
cation according to the Dutch National Guideline [11].
Patients with vitamin D deficiency (< 50 nmol/l) were
prescribed a daily dose of calcium (500 mg) and vitamin
D3 (800 IU) [11]. Each patient received alendronate
70 mg once weekly. After obtaining informed consent,
patients who agreed to participate in the study were ran-
domized to either phone call (PC) intervention or no
phone calls (no PC). Besides, we selected a reference
group of 30 postmenopausal osteopenic patients with a
recent fracture to observe the course of BTMs during
fracture repair. In all patients in the randomized groups
and in the reference group, blood was drawn for BTM
assessment at study start and after 3, 6, 9, and 12 months.
Patients in the PC group were called after 1, 4, and
12 months. All telephone calls were made by the same
experienced FLS nurse. These calls were particularly
meant to remind patients not to forget medication and to
exchange views about side effects. In case of clear evi-
dence of drug intolerance, patients were withdrawn from
the study and alternative treatments were offered.
Bone density measurement and VFA
A patient was diagnosed with osteoporosis if she fulfilled
the WHO criteria for osteoporosis (a T-score of ≤ − 2.5SD
at the total hip, femoral neck, or lumbar spine) or if she
had at least one vertebral fracture and a loss of height of
more than 25% on radiography or of more than 40% on
VFA, according to Genant’s classification [27]. Criteria
for osteopenia were a T-score between − 1.0 and −
2.5SD at the lumbar spine and/or hip and no morphomet-
ric abnormalities (Hologic DXA equipment, Hologic
Discovery QDR Series).
Bone turnover markers
P1NP was measured by means of radioimmunoassay
(RIA; Orion Diagnostica, Espoo, Finland) and s-CTX by
means of electrochemiluminescence immunoassay
(ECLIA; Elecsys 2010 Roche Mannheim, Germany).
Fasting serum samples were stored frozen at − 20 °C
within 1 h after blood sampling until analysis. P1NP and
s-CTX were assayed and expressed in concentrations and
in z-scores, using a Dutch Reference Values Group (350
women older than 50) [28]. Blood collection took place at
baseline (study start) and after 3, 6, 9, and 12 months, and
all samples were finally sent off as one batch for analysis
at the laboratory of the University Medical Centre,
Groningen, the Netherlands.
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Table 1 Studies on interventions with phone calls









Intervention Arm A: 24
Arm B: 25
Arm A: Patients met with
nursing staff at 12, 24, and






Arm B: Same as Arm A
except following each
interview, patients were
also presented with a graph
showing their response to
therapy based on BTM
measurements
Positive. Survival analysis
showed that the monitored
group increased
cumulative adherence to
therapy by 57% compared
with no monitoring.
There was a trend for the
monitored group to persist
with therapy for 25%










RCT USA Clinic/telephone Intervention 37 Patients received an
osteoporosis informational
brochure, BMD test, and
four telephone
consultations with a nurse
educator
Negative result nurse group
versus usual care





RCT UK Physicians’ offices Intervention 547 Monthly ibandronate tablet








and who stressed the
importance of adherence;
and a newsletter at
3 months
Positive. The PERSIST study
demonstrated that
persistence with treatment









RCT Multi-national Hospital-based and
academic clinics
Intervention 1189 Same as control except
patients also received
feedback on their response
to therapy based on BTM







intervention based on a
good BTMs response,
result was associated with
a significant improvement
in persistence. Persistence
was unchanged or lower
when reinforcement was
based on a stable or poor
BTM response
respectively
Control 1113 Patients received calcium,
vitamin D, and risedronate
(5 mg) with instructions
for taking the medication.







NRNCT US Clinic/telephone Intervention 188 Patients received phone calls






based on pharmacy and
clinical interview data was
significantly higher than
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Table 1 (continued)





and there was a significant
dose-response effect. The
results support the use of
psychological techniques
to improve adherence and














Intervention 80 Patients received a letter with
osteoporosis information
and an automated phone










Control 46 Usual care
Waalen 2009
[20]






Positive. Of 109 women in
the telephone-based
osteoporosis clinic group,
75 (68.8%) were using
osteoporosis medication at
1 year compared with 46
of 102 women (45.1%) in
the usual care group
(p < .001). The use of
osteoporosis medication
may be significantly im-
proved via a monthly tele-
phone follow-up






















NRCT Italy Telephone calls Intervention 382 Patients starting with
teriparatide received 1
phone call per week during
the first month, then 1
phone call per month and
per 3 months during the
following 5 and 12 months
Borderline positive. The
persistence rate of the
group following the
program was 85.6%, 8.2%
higher than that of the




occurred mainly at early
stages of the treatment due
to adverse events
Historical 398 Historical cohort
Stuurman-Bieze
2014 [23]
RCT Netherlands Pharmacy initiative Intervention 495 MeMO intervention.
Continuous monitoring of








sessions. In the usual care




compared to 19.0% of
patients in the intervention
group
Control 442 Usual care
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Evaluation of persistence with alendronate based
on the Dutch National Exchange Point
Pharmacies-GPs (LSP)
After study completion, dispensation data of all participants
were collected from the Dutch Landelijk Schakel Punt (LSP),
translated in English as National Exchange Point Pharmacies-
GPs [29] after verifying whether each patient had consented to
the use of personalized data stored in this database. Since
patients in the Netherlands are encouraged to store their iden-
tifiable healthcare and pharmacy data in the LSP, this database
offers accurate information on prescriptions and data on de-
liveries, including the name of the pharmacy, the date of pre-
scription, the number of prescribed tablets, the prescriber, and
the dosage regimen. Thus far, nationwide, more than 11 mil-
lion Dutch citizens (which is over 70% of the population)
consented to giving access to LSP. Pharmacy staff are legally
bound to request informed consent regarding the review of
individual dispense data.
Statistics
Data were analyzed using Statgraphics Centurion XVII soft-
ware (Version 17.1.08 for MS-Windows; Statpoint, Inc.,
Warrenton, VA, USA).
A power analysis was conducted using G*Power software
(Germany, version 3.1) to determine the number of patients
needed in this study. Two groups of women would have
bisphosphonates prescribed. Sample sizes per group were es-
timated a priori for two-sided significance level alpha = .05
and power = 80% using Fisher’s exact test for unequal propor-
tions in two independent groups. Proportions of patients (= %
medication compliant) with phone calls versus no phone calls
were compared in the analysis: the first proportion was 40%
(no phone calls) and the second proportion was 70% (phone
calls). Compliancy was scored by calculating the biologically
and statistically significant decrease (so-called least
significant change) in the two serum BTMs. The output
indicated that 42 patients would be needed in each group to
have a power of 80%. These numbers were corrected by 15%
both for non-parametric statistical tests and losts to follow-up:
the final numbers of patients estimated were (rounded up) 50
per group.
Comparison of phone call (PC) versus no phone call
(no PC) intervention effects on persistence
We used a logistic regression model comparing the binominal
variable intervention (PC = 1; no PC = 0) and persistence with
alendronate at 12 months (LSP Yes vs. No) as a binary out-
come variable. Besides least significant change (LSC), other
censors were studied using data from the reference group after
showing statistical feasibility of pooling. The outcomes of
LSC and censors applied in our FLS patients were compared
to the LSC criterion proposed by the IOF/ECTS Working
Group [30]. BTM levels and both the age- and gender-
adjusted near-Gaussian z-scores were analyzed. BTMs and
LSP results were analyzed separately according to time since
fracture, study start, and a fixed time of 180 days (as time
outcome variables). For this, linear models were used analyz-
ing BTMs at various time points with the fracture codes as
categorical factors. Since the outcomes at these various time
points were similar, we only report those at 180 days after
fracture (see Fig. 2). Measuring data of the reference group
were repeated at the various time points and pooled for further
analysis. Statistical changes between the BTM level or z-score
at study start before treatment and after alendronate treatment
were analyzed in order to find medication-compliant BTM
measures in accordance with LSP Yes or No. The binominal
censors explored were LSC, underrunning the median esti-
mates (<median; abbr. MedREF) from the pooled BTM levels
of the reference group as previously described [31] and un-
derrunning the calculated outcome BTM level of the median
after correction for outliers (< median absolute deviation;
abbr. MedMAD) [32]. Since near-Gaussian distribution was
observed and tested for the BTM levels of the reference group
Table 1 (continued)







RCT Italy Telephone calls Intervention Arm 1: 110
Arm 2: 111
Intervention group Arm 1
received information
materials and intervention











The special effort of devising
and providing additional
reminders did not prove
effectiveness
Control 113 Usual care.
Osteoporos Int (2018) 29:813–824 817
at the various points in time, we applied a consistency factor of
1.4826. For this study, we used LSCs (95% confidence, two-
sided) as previously reported for another Dutch cohort, i.e., z-
scores of 36% for P1NP and 29% for s-CTX [33]. Logistic
regression was applied to estimate odds ratios and their 95%
confidence intervals, using completed medication dispensa-
tion at 12 months (LSP Yes or No) and BTMs and PC and
no PC and the separate persistence parameter for both P1NP
and s-CTX (Yes = 1; No = 0) and fractures. Where applicable,
a p value of < .05 was considered statistically significant at the
95% confidence level.
Ethics
The study with number NL 35164.098.11 was approved by
the regional Medical Ethical Review Board (METC Zuidwest
Holland) and was carried out in accordance with the declara-
tion of Helsinki and the guidelines of the International
Conference on Harmonization Good Clinical Practice
(GCP). Written informed consent was obtained from all par-
ticipants included in the study and in the reference group.
Results
From June 2012 to January 2014, 881 postmenopausal wom-
en that attended the FLS of the Reinier de Graaf Gasthuis,
Delft, the Netherlands, were evaluated: 350 (40%) with oste-
oporosis, 399 (45%) with osteopenia, and 132 (15%) with a
normal T-score. Of the 350 osteoporotic patients, 119 (34%;
mean age 69.5 years (range 53–86)) consented to participate
in our telephone intervention study. After withdrawal for sev-
eral reasons, 45 completed the study in the PC group and 48 in
the no PC group. Obviously, reasons for dropping out were
known in the PC group (12 patients dropped out for GI rea-
sons and 3 patients dropped out for motivational issues). In
each case, dropping out did occur within the first 4 months of
the study based on self-reporting. Other non-oral osteoporosis
treatments were offered and accepted by six patients. In the no
PC group, dropping out was registered in LSP at 12 months
(LSP does not include documentation about the cases who
dropped out from the study). Subsequently, none of these
patients received other osteoporosis medication.
Of 30 osteopenic reference group patients, 23 gave the
adequate number of blood samples according to study proto-
col, see Fig. 1. Baseline characteristics of all participants are
listed in Table 2.
PC versus no PC
Censors indicate significant bisphosphonate-induced lower-
ing of the respective BTMs and were described as proportions
at each point in time using intention-to-treat (ITT) (n = 119)
and per-protocol (PP) (n = 93) analyses. LSP analysis accord-
ing to ITT revealed LSP PC—71.2% and no PC—67.9%
(p > 0.05).
Moreover, 93 patients who completed the study (PP) also
showed no significant difference in LSP between the PC
group and the no PC group (PC 75% and no PC 76%,
p > 0.05).
Bone turnover markers and LSP
Logistic regression using the binominal variable intervention
PC and no PC disclosed no significant relationship between




Consent with series of 5 blood 
samples (n=30)
n=350 (40%) T-score <-2.5SD
n=86 Excluded for Metabolic Bone Diseases (10%)




n=7 incomplete blood sample series
(23%)




(12 GI related, 3 movaonal)
NoPC (n=59)
11dropouts (19%)
(9 GI related, 2 movaonal)
NoPC (n=48)
Fig. 1 Study flowchart
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interventions to be combined (n = 93). In this group analysis,
we found an LSP Yes in more than 85% (range 85–94) of
those patients who had a P1NP decrease of more than 36%
LSC and an LSP Yes in nearly 100% of those who had an s-
CTX decrease of more than 29% LSC. Looking for a single
optimal BTM for persistence prediction, we compared previ-
ously reported LSCs and two other censors: median of refer-
ence group (MedREF) and median absolute deviation of ref-
erence group (MedMAD). (see Table 3).
Listed data represent optimal LSC cut-off values for
alendronate persistence at 12 months according to LSP for
P1NP and s-CTX. The outcomes P1NP and s-CTX levels
were expressed as identifiable patient numbers (Yes/No).
Censors were expressed at 3 and 12 months after study start.
Besides the data obtained in the current study, IOF recom-
mended cut-off values were also listed (see Table 3) [30,
34]. The results for P1NP and s-CTX at 3, 6, and 9 months
are comparable with the 12-month results (data not shown).
Table 2 Baseline characteristics






Per-protocol analysis N = 93 n = 45 (48%) n = 48 (52%) n = 23
Age: years (mean); distribution 69.5; 53–86 67.9; 55–78 69.4; 53–86 60.2; 51–74
Hip fracture; number (%) 7 (7%) 5 (11%) 2 (4%) 1 (4%)
Vertebral fracture; number (%) 6 (6%) 2 (4%) 4 (8%) –
Major fracture; number (%) 41 (44%) 21 (47%) 20 (42%) 6 (26%)
Minor fracture; number (%) 39 (43%) 17 (38%) 22 (46%) 16 (70%)
DEXAT-score hip: mean (*SD);
distribution (*SD)
− 2.2; − 0.3
to − 4.2
− 2.5; − 1.5
to − 4.2
− 2.0; − 0.3 to
− 3.7
− 1.7; − 0.4
to − 2.4
DEXAT-score lumbar spine mean (*SD);
distribution (*SD)
− 2.1; + 0.3
to − 4.3
− 2.4; − 0.5
to − 4.2
− 1.9; + 0.3 to
− 4.3
− 1.3; − 0.3
to − 2.5
VFA: number of prevalent vertebral loss
of height > 40% (%)
15 (16%) 4 (8%) 11 (23%) –
T-hip scores, T-lumbar spine scores, and VFA measures from the PC and no PC groups did not show a near-
Gaussian distribution. After checking for equal distributions using the Kolmogorov-Smirnov test, the medians of
the variables mentioned were compared applying both the non-parametric Wilcoxon-Mann-Whitney test and
Notched Box-and-Whisker plots. We found no significant differences in T-hip, T-lumbar spine, and VFA between
PC and no PC groups
Table 3 BTM compliance outcomes at 3 and 12 months
3 months versus baseline
Available BTMs in 86/93
patients (92%) n = 7
LSP = 0 (8%) n = 86













P1NP < 30 μg/L
MedMAD3












6 (7%) 10 (12%) 4 (4%) 50 (58%) 22 (25%) 16 (19%) 23 (27%)
Agreement 73
(85%)
80 (93%) 76 (88%) 82 (96%) 36 (42%) 64 (75%) 70 (81%) 63 (73%)
12 months versus baseline
Available BTMs in 65/93
patients (70%) n = 26
LSP = 0 (28%) n = 67











P1NP < 30 μg /L
MedMAD3













62(97%) 63 (98%) 52 (81%) 53 (83%) 60 (91%) 52 (78%)
1Defined as the least amount of change between measurements over time that must be exceeded before a change can be considered true (with a certain
confidence 2.77) in an individual
2 P1NPAND s-CTX values are calculated based on median of pooled reference postmenopausal group data (MedREF)
3 P1NP and s-CTX values are calculated based on medium of pooled data at time of study start*1.48 median absolute deviation of pooled data at time of
study start (MedMAD)
4 IOF proposed LSC percentages respectively P1NP 38% and s-CTX 56% in cohorts without previous fracture ≤ 3 months
5 Calculations based on IOF-proposed premenopausal reference values
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Using underrunning median values obtained from the refer-
ence group led to similar results, but only with use of the
MedREF censor.
Discussion
In this study, we found no favorable effects of a dedicated
telephone call intervention on standard care regarding persis-
tence with bisphosphonates at 12 months. Note that this study
was executed and analyzed within an FLS setting, which to
our knowledge has not been studied before. This study as a
whole encompasses real-life FLS practice with or without
telephone calls and also BTMs for monitoring medication
persistence per individual patient.
We were able to study persistence with BTMs for the anal-
ysis of identifiable pharmacy deliveries in the early postfrac-
ture phase and at 1-year follow-up. BTMs in the first 3 months
post fracture are notoriously hard to interpret because of the
bias caused by fracture repair in this phase. As we are inter-
ested in the effects of treatment in that early postfracture
phase, we studied BTMs in the randomized study groups on
alendronate and as a surplus in a group of postmenopausal
osteopenic women (as a non-treated reference group)
reflecting the natural course of BTMs post fracture.
To substantiate BTMs and the pharmacy deliveries in the
analysis of individual persistence, we cross-referenced the
identifiable patients in our study groups to a Dutch exchange
system on pharmacy deliveries (LSP). This system enables the
exchange of healthcare data on pharmacy deliveries among
authorized healthcare staff. First of all, the LSP system offers
an overview of prescribed medication, but secondly, it gener-
ates monitoring facilities of persistence, as nationwide more
than 11 million Dutch citizens (which is over 70% of the
population) consented to giving healthcare staff access to their
personal LSP data.
At the end of this study, we found out firstly that telephone
support of patients with an alendronate prescription after a
recent fracture is not of importance regarding persistence,
which was about 75% (after exclusion of 26 patients who
stopped taking bisphosphonates due to GI-related complaints
or motivational issues) in both the PC and the no PC groups at
1 year. This finding differs entirely from the persistence of
40% that was previously reported by Netelenbos and
Geusens [12]. However, their study was based on the general
osteoporotic population-based pharmacy deliveries of
alendronate and is not a reflection of those patients starting
alendronate soon after sustaining a fracture. Moreover, this
difference in persistence could also be explained by the less
intensive supervision of patients outside the closely monitored
conditions of an RCT. Our findings are in line with the persis-
tence of 74 to 88% found in the study on osteoporosis medi-
cation and persistence of Klop [13], who provided more
differentiated data on persistence, taking a recent fracture into
account as a discerning variable.
Although telephone interventions did not influence persis-
tence in our study, an important favorable effect of these
phone calls was that patients who stopped taking alendronate
were identified at an early stage. Of the patients who recently
started taking alendronate and then stopped, the majority re-
ported GI side effects as reason for stopping this medication.
Any undetected cessation of alendronate therapy should be
considered an FLS failure, which might be prevented by tele-
phone calls at an early stage and offering alternatives, such as
liquid or non-oral medication.
Alendronate persistence is crucial in the long-term treat-
ment for osteoporosis patients. Medication persistence in gen-
eral regarding chronic conditions is reported to be low, and the
World Health Organization (WHO) as well as the
International Osteoporosis Foundation (IOF) declared the
matter of persistence a major challenge to effective long-
term management [35]. It is unfortunate that no effects of
telephone intervention were confirmed. Finding no effects is,
however, in line with other non-FLS initiated studies, see
Table 1 [14–26, 34].
Nevertheless, a number of FLS-initiated actions need to be
taken to ensure persistence [36]. Firstly, personal encourage-
ment of taking medication should continue shortly after any
traumatic and painful event [37]. Secondly, it is important to
try and solve the matter of underestimating the impact of sus-
taining a fracture and the low attendance of FLS patients, as
we have shown previously in an FLS questionnaire study [11].
This low attendance at FLSs is a world-wide phenomenon,
resulting in a major care gap. This notion was one of the main
starting points for the CtF campaign.
For observing persistence after initiating alendronate,
BTMs can be used. However, any biomarker used to monitor
persistence may be influenced by fracture repair and bone
union. Moreover, the effects of fracture repair could last for
more than 800 days, as was shown by data of our untreated
reference group ((Fig. 2 (2.4 and 2.5)). Therefore, we com-
pared the course of BTMs since fracture, since start of study,
and also at 180 days post fracture, based on data of the min-
imal wash-out period of fracture effects [38, 39]. Notably, the
outcomes at the various time points were similar.
Our findings support the results of the previous TRIO study
that compared the pers is tence with several oral
bisphosphonates by assessing P1NP and s-CTX and found
that the use of BTMs is feasible [36]. In addition, we studied
the individual persistence and our study revealed a promising
exactness for s-CTX at 3 months. Compared to s-CTX preci-
sion, the reliability of P1NP for individual persistence at
12 months is somewhat lower, as is shown in Table 3.
Notably, data of the current study are based on LSP out-
comes per identifiable patient, while previous data were re-
ported at group level. In general, persistence indicated via
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P1NP and s-CTX agreed fairly well for P1NP, i.e., 36% (cur-
rent study) versus 38% (TRIO study), but the LSC cut-off
point for s-CTX was clearly low in the current study (29 vs.
56% (TRIO study)). Note the importance of the time point at
which the BTM samples were taken and of the patient’s phys-
ical condition at that moment. In our study, blood samples for
BTM analysis were taken in recent fracture patients. Our next
step was to study individual persistence after correction for
outlying data due to biological variations caused by the very
long wash-out period of fracture and fracture repair. Besides
the median of the reference group (MedREF) to calculate un-
derrunning BTMs on alendronate treatment, we also com-
pared persistence after correction for outliers as calculated
with the MedMAD (see statistical paragraph) with most com-
monly used LSCs. Reference group-derived censors were
compared to rule out effects for existing skewness and kurto-
sis of alendronate BTM suppression and to avoid statistical
bias of existing outliers and small sample size. However, use
of reference group-derived censors revealed no improvement
in the prediction of alendronate persistence.
Several LSC thresholds have been reported using automat-
ed and manual assays. Roche Elecsys as used for this study is
a commercially available assay and is widely used. Previously
reported LSC declines were s-CTX lower than 27% and P1NP
lower than 20% [30]. Clearly different LSCs have also been
reported for several bisphosphonates, those for alendronate
ranging from 38 to 56% [30, 36]. These variations make it
questionable whether the percentages reported for the same
bisphosphonate can also be ascribed to related factors, for
example, retrospective or prospective cohort analysis, ethnic-
ity, or time of fracture repair. Moreover, in previous studies,
calculations were based on patients with older osteoporotic
fractures [28, 30, 33, 36]. Therefore, we decided to study
real-life outcome data from this RCT describing a prospective
Dutch FLS treated group shortly after fracture using previous-
ly reported Dutch LSC cut-off levels.
2.5 Reference group 2.6 Reference group
2.4 No PC group2.3 No PC group
2.1 PC group2.2 PC group
Fig. 2 (2.1–2.6) P1NP and s-
CTX z-scores versus time period
180 days post fracture.
Scatterplots of P1NP and s-CTX
z-scores depicted at 180 days post
fracture. Each line represents an
individual patient. Data of the PC
group and the no PC group on
alendronate are depicted in the
upper panels (2.1 and 2.2)
respectively in the middle panels
(2.3 and 2.4). Data of the
postmenopausal reference group
without alendronate therapy are
depicted in the lower panels (2.5
and 2.6), lines at z-score = 0.0
show the mean of the applied
parametric 95% reference interval
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In our study, the presumed cut-off values reflecting persis-
tence were rather similar to those reported by Rogers [30],
which were 28% for P1NP and 25% for s-CTX versus 36%
and 29%, respectively, in our study. Regarding our calculated
cut-off values, assessment of s-CTX at 3 months revealed to
be best predictive on BTMs for 1-year alendronate persis-
tence. In more detail, in our study, an LSC of s-CTX lower
than 29% or a level of less than 415 ng/L (MedREF) at
3 months agreed with nearly all except seven non-delivery
cases. By contrast, these s-CTX cut-offs failed in 4 LSP-
confirmed deliveries, see Table 3.
Comparing our results with the IOF-proposed LSCs
showed less favorable results on pharmacy deliveries. The
IOF cut-off levels, however, were not based on osteoporotic
women with recent fractures [30, 36].
In comparison to the high agreement regarding LSCs for
both the time points 3 and 12 months, similarity in results was
found in using the reference group-based censor MedREF (s-
CTX < 415 ng/L and P1NP < 53 μg/L); at 3 and 12 months, s-
CTX was 96 and 98%, respectively, and P1NP was 76 and
97%, respectively.
By contrast, less agreement was found at 3 months using
the reference group-based censor corrected for outliers
MedMAD (s-CTX lower than 233 ng/L and P1NP lower than
30 μg/L); this was 75% for s-CTX and 42% for P1NP, respec-
tively, although the difference decreased at 12 months and
went up to 83% for s-CTX and 81% for P1NP.
This study has some important limitations. Firstly, the sam-
ple size is fairly small but our results on the absence of effects
of telephone calls are in our opinion robust and clear. A sec-
ond limitation is the use of the non-treated reference group,
which is small as well, but accepted statistical techniques such
as pooling data made the outcome of the reference group
useful and valuable, especially for the calculated MedREF
and MedMAD besides LSC. Thirdly, a limitation worth men-
tioning may be the introduction of a potential Hawthorne ef-
fect (five blood drawings) towards persistence.
An important strength of this study was the use of identifi-
able LSP data, which served as proxy for persistence with any
medication, for example, treatment with alendronate.
To conclude, this FLS-initiated study showed an
alendronate persistence of 75% after correction for individuals
who had to stop taking bisphosphonates. Telephone interven-
tion did not have an add-on effect to alendronate persistence in
this study, but offered the advantage of early detection of any
reason for stopping medication. LSC, particularly that of s-
CTX (compared to baseline BTM level) after early drop out (1
to 3 months), is a practical measure to be used in an FLS real-
life situation to analyze persistence with alendronate after
1 year providing use of adequate cut-off points (Fig. 3). The
weakness of this study is that outcome results have been re-
ported in a small number of patients. Therefore, more FLS
studies are needed to strengthen LSC data while comparing
outcomes for different treatments and different populations.
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